Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 5/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13713688 | 0.85 | CARM1 (0.49) | CHRM2CHRM1CHRM3CETPDAO | |
| SCHEMBL22957905 | 0.83 | CHRM2 (0.66) | CHRM2CHRM1CHRM3CNR1CETP | |
| SCHEMBL10087661 | 0.81 | CHRM2 (0.68) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4984619 | 0.81 | CETP (0.49) | CHRM2CHRM1CHRM3CNR1CETP | |
| SCHEMBL22957874 | 0.81 | CHRM2 (0.52) | CHRM2CHRM1CHRM3CNR1CETP | |
| SCHEMBL4972921 | 0.80 | CETP (0.45) | CHRM2CHRM1CHRM3CNR1CETP | |
| SCHEMBL22957759 | 0.79 | CETP (0.48) | CHRM2CHRM1CHRM3CNR1CETP | |
| SCHEMBL28218524 | 0.79 | SIGMAR1 (0.50) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2090888 | 0.78 | CHRM2 (0.58) | CHRM2CHRM1CHRM3CNR1CETP | |
| SCHEMBL9957662 | 0.78 | CNR1 (0.49) | CHRM2CHRM1CHRM3CNR1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | CHRM2 4111/4885CHRM1 3581/4885CHRM3 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.